Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALA 
Kala Pharmaceuticals Inc (KALA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KALA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.66M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta -1.82 | 52 Weeks Range 2.92 - 11.20 | Updated Date 08/15/2025 |
52 Weeks Range 2.92 - 11.20 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.96 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -2.93 | Actual -1.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.51% | Return on Equity (TTM) -576.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54647792 | Price to Sales(TTM) 1.16 |
Enterprise Value 54647792 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 7021040 | Shares Floating 3685223 |
Shares Outstanding 7021040 | Shares Floating 3685223 | ||
Percent Insiders 1.91 | Percent Institutions 64.58 |
Upturn AI SWOT
Kala Pharmaceuticals Inc
Company Overview
History and Background
Kala Pharmaceuticals, Inc. was founded in 2009 and focused on developing innovative therapies for eye diseases. It went public in 2017. Kala encountered financial challenges, including a reverse stock split in 2021 and eventually ceased operations.
Core Business Areas
- Dry Eye Disease: Focused on therapies to treat dry eye disease, primarily with its product EYSUVIS.
- Post-Operative Inflammation and Pain: Developed and commercialized products for inflammation and pain following ocular surgery.
Leadership and Structure
The leadership structure involved a CEO, CFO, and various VPs responsible for clinical development, commercial operations, and other functions. Information about the leadership structure is limited post operations.
Top Products and Market Share
Key Offerings
- EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%: EYSUVIS was an FDA-approved corticosteroid indicated for the short-term treatment of the signs and symptoms of dry eye disease. Market share data is limited due to the company's operational status. Competitors included Restasis (AGN), Xiidra (NOVN), and other dry eye treatments.
- INVELTYS (loteprednol etabonate ophthalmic suspension) 1%: INVELTYS was an FDA-approved corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Market share data is limited due to the company's operational status. Competitors included generic prednisolone and other post-operative anti-inflammatory treatments.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is characterized by significant competition and a high degree of innovation. The dry eye market has grown, driven by an aging population and increased digital screen use.
Positioning
Kala Pharmaceuticals positioned itself as a specialist in eye care, with a focus on nanomedicine-based therapies. Due to its discontinuation of operations, its competitive advantage is no longer relevant.
Total Addressable Market (TAM)
The dry eye disease and post-operative inflammation markets represented a multi-billion dollar opportunity. Kala aimed to capture a significant share, but its discontinuation occurred before achieving substantial penetration.
Upturn SWOT Analysis
Strengths
- FDA-approved products (EYSUVIS, INVELTYS)
- Nanoparticle technology platform (AMPPLIFY)
- Experienced management team (before discontinuation)
Weaknesses
- Limited financial resources
- Heavy reliance on few products
- Inability to achieve sustained profitability
Opportunities
- Expansion into new ophthalmic indications
- Partnerships or licensing agreements
- Geographic expansion (before discontinuation)
Threats
- Competition from established players
- Patent expirations
- Pricing pressure from payers
Competitors and Market Share
Key Competitors
- AGN
- NOVN
- ALVR
Competitive Landscape
Kala Pharmaceuticals faced intense competition from established players with larger market share and greater resources. Its competitive advantages were based on its nanomedicine platform, but it ultimately could not overcome financial challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was limited, with initial revenue growth followed by financial struggles.
Future Projections: No future projections are available as Kala Pharmaceuticals is no longer operating.
Recent Initiatives: Recent initiatives focused on commercializing EYSUVIS and INVELTYS, but they were insufficient to sustain the company.
Summary
Kala Pharmaceuticals faced significant challenges, despite having FDA-approved products and innovative technology. The company's inability to achieve profitability and manage its financial resources led to its discontinuation of operations. It needed to secure partnerships, expand its product pipeline, and effectively manage its debt to survive. Ultimately, its operational and financial struggles resulted in poor shareholder returns and the company's demise.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Press Releases (historical)
- Third-party financial websites
Disclaimers:
This analysis is based on historical data and publicly available information. It should not be considered investment advice. Kala Pharmaceuticals Inc. is no longer an operating entity, thus limiting the relevance of the analysis for current investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | Interim CEO, President & COO Mr. Todd Bazemore | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.kalarx.com |
Full time employees 38 | Website https://www.kalarx.com | ||
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.